Roche is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market and is the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche employs roughly 74,000 people in 150 countries. The Group has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai.
Roche's pioneering approach to healthcare innovation enables us to deliver significant benefits to patients as well as to healthcare providers and systems. In our vision of the future, therapies will be available for many of today's untreatable diseases, it will be possible to optimize drug efficacy and safety, and effective strategies will be in place for preventing disease. Early diagnosis and improved new treatments will significantly reduce the need for expensive surgical operations and long hospital stays.
While this vision is an aspiration for the future, Roche has begun pioneering the path, with a wide range of products and services available to:
determine disease predisposition
provide health information that can be acted upon to prevent or delay the onset of illness
treat numerous diseases and conditions
monitor the progress of therapy
Roche in China
The Roche Group has four companies and a research center in China, representing its core pharmaceuticals and diagnostics businesses. Located in Hong Kong and Shanghai, they employ some 1300 people. In collaboration with the two Chinese National Human Genome Centers, Roche is conducting genetic epidemiology studies to identify genetic predispositions to diseases such as diabetes or Alzheimer’s.